http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110642838-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2019-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110642838-B |
| titleOfInvention | EGFR inhibitor and its preparation and application |
| abstract | The present invention relates to a 2-aminopyrimidine derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I) and the use of the compound in the preparation of preventing or treating epidermal growth factor receptor (EGFR) kinase-related diseases, In particular use for the prevention or treatment of epidermal growth factor receptor kinase-related cancers. wherein each substituent in formula (I) is the same as defined in the specification |
| priorityDate | 2018-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.